Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
boston blog main
deals
4
×
life sciences
national blog main
national top stories
san francisco blog main
4
×
startups
4
×
boston top stories
new york blog main
new york top stories
san francisco top stories
alnylam pharmaceuticals
ipo
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
sickle cell disease
vc
vir biotechnology
abbvie
acetylon pharmaceuticals
akouos
allergan
amag pharmaceuticals
ambys medicines
amunix
anirvan ghosh
astrazeneca
azacitidine
beijing
beta-thalassemia
biogen
bluerock therapeutics
boston
boulder/denver blog main
boulder/denver top stories
brii bio
brii biosciences
What
medicines
4
×
new
biotech
deal
startup
acquisitions
adds
aiming
aims
alliance
ambys
announced
approach
areas
based
big
bio
biosciences
bio’s
brii
called
ceo
collabs
control
covid
daniel
deadly
debuted
debuts
developing
disease
diseases
drug
drugs
earlier
epigenetic
epigenetics
field
flagship’s
formed
Language
unset
Current search:
medicines
×
biotech
×
deals
×
startups
×
" san francisco blog main "
×
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
